Here’s why 23-year-old Lau­ra Dem­ing is bet­ting $22M on an­ti-ag­ing R&D

An MIT stu­dent at 14, a drop-out at 16 and an en­tre­pre­neur run­ning her own small biotech ven­ture fund at 17, Lau­ra Dem­ing is not your typ­i­cal ven­ture ex­ec. Now, at 23, she’s raised a $22 mil­lion fund — her sec­ond for the Longevi­ty Fund — that will look to in­vest in more com­pa­nies like Uni­ty Biotech­nol­o­gy which are look­ing to ad­vance new an­ti-ag­ing drugs.

An­ti-ag­ing is just now com­ing in­to vogue, as Uni­ty Biotech­nol­o­gy’s re­cent $151 mil­lion B round in­di­cates. But Dem­ing got start­ed long be­fore an­ti-ag­ing gained some trac­tion with tra­di­tion­al VCs. Now, as the field gains steam, she plans on build­ing on her bets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.